Document:

ex4-50.htm

Exhibit 4.50

FOURTEENTH SUPPLEMENTAL INDENTURE

 

FOURTEENTH SUPPLEMENTAL INDENTURE, dated as of October 23, 2013 (the “Fourteenth Supplemental Indenture”), by and among Akcinė bendrovė SANITAS (Public limited liability company SANITAS), a company continued under the laws of the Republic of Lithuania (“Sanitas”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).

 

WHEREAS, each of the Company, Valeant Pharmaceuticals International, Inc. (“Parent”), the indirect parent of the Company, and the Subsidiary Guarantors (as defined in the Indenture referred to below) has heretofore executed and delivered to the Trustee an Indenture, dated as of November 23, 2010 (the “Indenture”), providing for the issuance of 6.875% Senior Notes due 2018 (the “Securities”);

 

WHEREAS, Sanitas agrees to provide a full and unconditional guarantee (the “Guarantee”) of the obligations of the Company under the Securities and the Indenture on the terms and conditions set forth herein;

 

WHEREAS, pursuant to Section 9.1 of the Indenture, the Company, the Trustee and Sanitas are authorized to execute and deliver this Fourteenth Supplemental Indenture; and

 

WHEREAS, the Company has complied with all conditions precedent provided for in the Indenture relating to the Fourteenth Supplemental Indenture.

 

NOW THEREFORE, in consideration of the foregoing, the parties hereto mutually covenant and agree for the equal and ratable benefit of the Holders as follows:

 

1.           Definitions.  Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Indenture.

 

2.           Guarantee.  Sanitas hereby agrees to provide a full and unconditional guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including, but not limited to, Article 10 thereof.

 

3.           Effectiveness of Fourteenth Supplemental Indenture.  This Fourteenth Supplemental Indenture shall become effective upon the execution and delivery of this Fourteenth Supplemental Indenture by the Company, Sanitas and the Trustee.

 

4.           Indenture Remains in Full Force and Effect.  This Fourteenth Supplemental Indenture shall form a part of the Indenture for all purposes and, except as supplemented or amended hereby, all other provisions in the Indenture and the Securities, to the extent not inconsistent with the terms and provisions of this Fourteenth Supplemental Indenture, shall remain in full force and effect.

 

5.           No Recourse Against Others.  No stockholder, officer, director or incorporator, as such, past, present or future of Sanitas shall have any personal liability under this Guarantee, the Securities, the Indenture or this Fourteenth Supplemental Indenture by reason of his, her or its status as such stockholder, officer, director or incorporator.

 

  

1

  

 

6.           Headings.  The headings of the Articles and Sections of this Fourteenth Supplemental Indenture are inserted for convenience of reference and shall not be deemed a part thereof.

 

7.           Counterparts.  This Fourteenth Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.

 

8.           Governing Law.  This Fourteenth Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflicts of laws.

 

9.           Trustee Disclaimer.  The Trustee is not responsible for the validity or sufficiency of this Fourteenth Supplemental Indenture nor for the recitals herein.

 

 

[Intentionally Left Blank]

 

  

2

  

 

IN WITNESS WHEREOF, the parties hereto have caused this Fourteenth Supplemental Indenture to be duly executed as of the day and year first written above.

 

	
Company:

	
VALEANT PHARMACEUTICALS INTERNATIONAL

	  	  	  	  
	  	
By:   

	
/s/ Howard B. Schiller

	  
	  	  	
Name:   

	
Howard B. Schiller

	  	  	
Title:

	
Executive Vice President and Chief Financial Officer

	  	  	  	  

	
Sanitas:

	
Akcinė bendrovė SANITAS

	  	  	  	  
	  	
By:   

	
/s/ Saulius Žemaitis

	  
	  	  	
Name:   

	
Saulius Žemaitis

	  
	  	  	
Title:

	
General Manager

	  
	  	  	  	  

 

 

 

[Signature Page to Thirteenth Supplemental Indenture to November Indenture]

  

  

  

 

	
Trustee:

	
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.

as Trustee

	  	  	  	  
	  	
By:   

	
/s/ Teresa Petta

	  
	  	  	
Name:   

	
Teresa Petta

	  	  	
Title:

	
Authorized Signatory

	  	  	  	  

 

 

 

 

 

[Signature Page to Thirteenth Supplemental Indenture to November Indenture]ex4-51.htm

Exhibit 4.51

FIFTEENTH SUPPLEMENTAL INDENTURE

 

FIFTEENTH SUPPLEMENTAL INDENTURE, dated as of October 23, 2013 (the “Fifteenth Supplemental Indenture”), by and among Akcinė bendrovė SANITAS (Public limited liability company SANITAS), a company continued under the laws of the Republic of Lithuania (“Sanitas”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”) and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).

 

WHEREAS, each of the Company, Valeant Pharmaceuticals International, Inc. (“Parent”), the indirect parent of the Company, and the Subsidiary Guarantors (as defined in the Indenture referred to below) has heretofore executed and delivered to the Trustee an Indenture, dated as of September 28, 2010 (the “Indenture”), providing for the issuance of 6.75% Senior Notes due 2017 and 7.00% Senior Notes due 2020 (collectively, the “Securities”);

 

WHEREAS, Sanitas agrees to provide a full and unconditional guarantee (the “Guarantee”) of the obligations of the Company under the Securities and the Indenture on the terms and conditions set forth herein;

 

WHEREAS, pursuant to Section 9.1 of the Indenture, the Company, the Trustee and Sanitasare authorized to execute and deliver this Fifteenth Supplemental Indenture; and

 

WHEREAS, the Company has complied with all conditions precedent provided for in the Indenture relating to the Fifteenth Supplemental Indenture.

 

NOW THEREFORE, in consideration of the foregoing, the parties hereto mutually covenant and agree for the equal and ratable benefit of the Holders as follows:

 

1.           Definitions.  Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Indenture.

 

2.           Guarantee.  Sanitas hereby agrees to provide a full and unconditional guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including, but not limited to, Article 10 thereof.

 

3.           Effectiveness of Fifteenth Supplemental Indenture.  This Fifteenth Supplemental Indenture shall become effective upon the execution and delivery of this Fifteenth Supplemental Indenture by the Company, Sanitas and the Trustee.

 

4.           Indenture Remains in Full Force and Effect.  This Fifteenth Supplemental Indenture shall form a part of the Indenture for all purposes and, except as supplemented or amended hereby, all other provisions in the Indenture and the Securities, to the extent not inconsistent with the terms and provisions of this Fifteenth Supplemental Indenture, shall remain in full force and effect.

 

5.           No Recourse Against Others.  No stockholder, officer, director or incorporator, as such, past, present or future of Sanitas shall have any personal liability under this Guarantee, the Securities, the Indenture or this Fifteenth Supplemental Indenture by reason of his, her or its status as such stockholder, officer, director or incorporator.

 

  

1

  

 

6.           Headings.  The headings of the Articles and Sections of this Fifteenth Supplemental Indenture are inserted for convenience of reference and shall not be deemed a part thereof.

 

7.           Counterparts.  This Fifteenth Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.

 

8.           Governing Law.  This Fifteenth Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflicts of laws.

 

9.           Trustee Disclaimer.  The Trustee is not responsible for the validity or sufficiency of this Fifteenth Supplemental Indenture nor for the recitals herein.

 

 

[Intentionally Left Blank]

 

  

2

  

 

IN WITNESS WHEREOF, the parties hereto have caused this Fifteenth Supplemental Indenture to be duly executed as of the day and year first written above.

 

	
Company:

	
VALEANT PHARMACEUTICALS INTERNATIONAL

	  	  	  	  
	  	
By:   

	
/s/ Howard B. Schiller

	  
	  	  	
Name:   

	
Howard B. Schiller

	  	  	
Title:

	
Executive Vice President and Chief Financial Officer

	  	  	  	  

	
Sanitas:

	
Akcinė bendrovė SANITAS

	  	  	  	  
	  	
By:   

	
/s/ Saulius Žemaitis

	  
	  	  	
Name:   

	
Saulius Žemaitis

	  
	  	  	
Title:

	
General Manager

	  
	  	  	  	  

 

 

 

[Signature Page to Fourteenth Supplemental Indenture to September Indenture]

  

  

  

	
Trustee:

	
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.

as Trustee

	  	  	  	  
	  	
By:   

	
/s/ Teresa Petta

	  
	  	  	
Name:   

	
Teresa Petta

	  	  	
Title:

	
Authorized Signatory

	  	  	  	  

 

 

 

 

 

[Signature Page to Fourteenth Supplemental Indenture to September Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]